The FDA Has Accepted And Granted Priority Review To The Biologics License Application For Daiichi Sankyo/Merck's Patritumab Deruxtecan For Pretreated Locally Advanced Or Metastatic EGFR-Mutated Non-small Cell Lung Cancer
Author: Benzinga Newsdesk | December 22, 2023 09:04am